Stockreport

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia [Yahoo! Finance]

Addex Therapeutics Ltd - American Depositary Shares  (ADXN) 
PDF biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out c [Read more]